Literature DB >> 33906272

[Expert consensus on the management of diabetic patients with cardiovascular diseases].

Y H Sun1, K Chen2, X Chen3, W J Gu2, Y L Guo4, Y J Li2, T Liu5, D Q Peng6, Y M Mu2, C S Ma5.   

Abstract

Diabetes is the most important comorbidity of cardiovascular disease, and cardiovascular disease is the main cause of mortality and disability of patients with type 2 diabetes. In order to standardize the diagnosis and treatment of patients with diabetes and cardiovascular disease, the National Health Commission Capacity Building and Continuing Education Center organized the experts from the field of cardiology and endocrinology systematically reviewing the research progresses and expert experiences of relevant disciplines from home and abroad, and formulated this consensus. This consensus covers the diagnosis, drug treatment, and risk factor management for patients with diabetes and cardiovascular disease (including atherosclerotic cardiovascular disease and heart failure) from the perspective of cardiovascular disease and diabetes management aiming to strengthen the comprehensive management of patients and ultimately to improve the prognosis of patients. The management of cardiovascular diseases mainly includes the management of blood pressure, blood lipids, anti-thrombosis, anti-myocardial ischemia, anti-ventricular remodeling and so on. Diabetes management mainly includes lifestyle intervention (including diet, exercise, weight loss, etc.), anti-hyperglycemia therapy (including drugs and insulin), blood glucose monitoring, and hypoglycemic prevention. In addition, specific clinical recommendations are given to patients with special health care needs such as diabetic nephropathy, elderly (>75 years), and cardiovascular critical illness.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33906272     DOI: 10.3760/cma.j.cn112138-20201208-00999

Source DB:  PubMed          Journal:  Zhonghua Nei Ke Za Zhi        ISSN: 0578-1426


  1 in total

Review 1.  A Health Technology Assessment Based on Chinese Guidelines: Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Type 2 Diabetes Complicated with Cardiovascular Disease.

Authors:  Zeyu Xie; Jinjian Li; Sensen Yang; Weishang Deng; Jisheng Chen
Journal:  Ther Clin Risk Manag       Date:  2022-08-30       Impact factor: 2.755

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.